Court extends Athenex claims-objection deadline to February 22, 2027 as $6.3 million of claims remain unresolved
ElevenFlo ·
Athenex's liquidation plan has been effective since September 22, 2023, and on November 16, 2026 the court extended the deadline to object to claims to February 22, 2027 Dkt. 1176. Four claims filed by two ChongQing pharmaceutical companies, totaling $6,307,713, remain unresolved Dkt. 1174. General unsecured creditors had received nothing as of September 30, 2026, and the debtor's report for that quarter targets a final-decree application by December 31, 2026 Dkt. 1168.
Jump to section
The liquidation plan has been effective since September 22, 2023. Secured, administrative and priority claims have been paid in full. General unsecured creditors had received nothing as of September 30, 2026.
Athenex, Inc. is administering claims under a plan of liquidation that the court confirmed on September 12, 2023 Dkt. 595 and that became effective on September 22, 2023 Dkt. 621. The affiliated debtors' cases closed on the effective date, so Athenex, Inc. is the only case still open Dkt. 1151. The post-effective-date debtor and Emerald Capital Advisors, as trustee of the Athenex Liquidating Trust, are working through the last disputed claims.
On November 16, 2026, the court extended their deadline to object to claims through February 22, 2027. It did so without prejudice to further extensions Dkt. 1176. In a November 4 supplement responding to the court's October 26 order on the motion, the movants identified four unresolved claims filed by ChongQing Taihao Pharmaceutical Co Ltd and ChongQing Sintaho Pharmaceutical Co Ltd. Together they total $6,307,713. The movants said the DSV adversary proceeding closed on October 30, 2026. That left the BCN adversary proceeding as the only remaining proceeding involving claims, and its parties were working toward a consensual dismissal stipulation Dkt. 1174. The debtor's report for the quarter ended September 30, 2026 anticipated an application for a final decree by December 31, 2026 Dkt. 1168. The new objection deadline falls after that date.
Secured and priority creditors have been paid in full, unsecured creditors not at all
The post-confirmation report for the quarter ended September 30, 2026 shows administrative, secured and priority claims allowed and paid in full. It lists $3,000,000 of allowed general unsecured claims with no payments and 0% anticipated paid. Its notes, however, say the allowed amount and the distribution percentage remain unknown while the liquidating trust reconciles and resolves disputed claims. The notes also call the administrative, secured and priority figures estimates subject to change Dkt. 1168. The report for the quarter ended March 31, 2026 also estimated allowed general unsecured claims at $3,000,000 Dkt. 1151.
| Claim class | Allowed | Paid cumulatively | Anticipated paid |
|---|---|---|---|
| Secured | $45,394,000 | $45,394,000 | 100% |
| Priority | $94,264 | $94,264 | 100% |
| Administrative | $86,198 | $86,198 | 100% |
| General unsecured | $3,000,000 | $0 | 0% |
The report shows $15,302 of cash disbursements in the quarter and $3,856,660 since the effective date. Preconfirmation professional fees and expenses of $9,465,762 have been approved and paid, mostly from an escrow account funded during the case and managed by lead counsel Dkt. 1168. The March 2026 report named the largest recipients: Pachulski Stang Ziehl & Jones ($2,441,549), MERU LLC ($1,494,035), Sullivan & Cromwell LLP ($1,277,195), Cassel Salpeter & Co., LLC ($1,060,864) and Porzio, Bromberg & Newman ($1,013,557) Dkt. 1151.
The trust has also cut off claimants that did not supply tax information. On May 6, 2026, the trustee gave notice about claimants that had not returned IRS Form W-8 or W-9 within 180 days of the trust's August 8, 2025 request. Those claimants had forfeited their distributions, which become unclaimed property for redistribution to other creditors. The trustee said it would consider, at its sole discretion, forms received by June 1, 2026 Dkt. 1152.
Three extensions in 2026 narrowed the disputed claims to four ChongQing claims
Three orders in 2026 moved the claims-objection deadline. The March 16 order extended it to June 25, 2026. It covered the claims on its Schedule 1, claims amended or filed after the motion, and claims of defendants in pending adversary proceedings Dkt. 1147. The July 17 order moved the deadline to October 23, 2026, with a schedule listing claims of the two ChongQing companies and Johnson Lau Dkt. 1161. The November 16 order set February 22, 2027 Dkt. 1176.
| Claimant | Claim | Scheduled amount | Status |
|---|---|---|---|
| ImmunityBio, Inc. | 10016 | $14,752,929.80 | Disallowed and expunged under the March 11, 2026 settlement order Dkt. 1143 |
| Exyte U.S., Inc. | 10317 | $8,478,929.80 | Allowed as a general unsecured claim of $4,662,926.88 under the same order Dkt. 1143 |
| Johnson Lau | 10324 | $2,543,992.94 | Described as allowed in the trustee's June 25, 2026 declaration Dkt. 1156 |
| Johnson Lau | 10325 | $0.00 | Disallowed as a duplicate on August 12, 2026 Dkt. 1165 |
| ChongQing Sintaho Pharmaceutical Co Ltd | 10075 | $5,134,650.00 | Unresolved |
| ChongQing Sintaho Pharmaceutical Co Ltd | 10073 | $731,948.00 | Unresolved |
| ChongQing Taihao Pharmaceutical Co Ltd | 10071 | $372,890.00 | Unresolved |
| ChongQing Taihao Pharmaceutical Co Ltd | 10072 | $68,225.00 | Unresolved |
A settlement resolved the two largest claims. On March 11, 2026, the court approved the trustee's Rule 9019 settlement with ImmunityBio, Inc. and Exyte U.S., Inc. It covered disputes under a Design/Build Agreement and an Asset Purchase Agreement for a facility in Dunkirk, New York. ImmunityBio's claim was disallowed and expunged. Exyte's claim was fixed and allowed as a general unsecured claim of $4,662,926.88. The trustee's rights under both agreements were assigned to ImmunityBio free and clear, and the court found ImmunityBio a good-faith purchaser under section 363(m). Exyte's adversary proceeding against Athenex was remanded to the Supreme Court of New York, Erie County. The order leaves to that court whether ImmunityBio assumed obligations under the agreements. If Exyte wins a judgment against ImmunityBio there, its distributions from the estate may be offset against that judgment dollar for dollar Dkt. 1143.
Johnson Lau, the debtor's former President and CEO, held two claims that survived an earlier omnibus objection: claim 10324 for $2,543,992.94 and claim 10325 for $0. The trustee objected to claim 10325 as a duplicate on June 25, 2026 Dkt. 1155. Its supporting declaration stated that claim 10324 remains an allowed claim Dkt. 1156. On August 12, 2026, the court sustained the objection and disallowed claim 10325 in its entirety Dkt. 1165. Separately, Beloteca, Inc. withdrew claim 10039 on March 13, 2026 Dkt. 1144.
Until the BCN matter is resolved, the trustee reserves its right to object to any claims in BCN's favor, including claims arising under section 502(h) Dkt. 1174. The target date for a final-decree application has moved with each quarterly report: June 20, 2026 in the March report Dkt. 1151, August 31, 2026 in the June report Dkt. 1160 and December 31, 2026 in the September report Dkt. 1168.
A failed drug approval led to a sale process and a liquidation plan within four months
Athenex was founded in 2003 and based in Buffalo, New York. It was an oncology-focused biopharmaceutical company with two segments: an Oncology Innovation Platform built around NKT cell therapy for solid tumors, and a Commercial Platform. The first-day declaration of chief restructuring officer Nicholas K. Campbell traces the filing to the FDA's February 2021 refusal to approve the company's new drug application for Oral Paclitaxel. The declaration says that refusal hurt the company's ability to attract investment and capital. Product sales rose 33% to $90.9 million in 2022, but the company lost $104.4 million that year and carried an accumulated deficit of $1,016.8 million Dkt. 18.
During 2022 the company raised cash in four ways. It sold its Dunkirk, New York manufacturing facility to ImmunityBio for approximately $40 million. It entered an $85 million revenue interest purchase agreement with Sagard Healthcare Partners and Oaktree Capital Management. It sold its Chinese manufacturing operations for approximately $11 million. It raised approximately $30 million in a public offering Dkt. 18.
Athenex filed for chapter 11 in the Southern District of Texas on May 14, 2023 Dkt. 1. It proposed an expedited 45-day sale process for its Athenex Pharmaceutical Division, Athenex Pharma Solutions, Cell Therapy and Orascovery businesses, with a June 12, 2023 bid deadline and a possible June 30 closing. It also sought to protect estimated net operating losses of approximately $511 million Dkt. 18.
The debtors filed a combined disclosure statement and plan of liquidation on July 26, 2023 Dkt. 468 and the solicitation version on August 1 Dkt. 501. An amended plan supplement followed on September 5 Dkt. 573. On September 12, 2023, the court granted final approval of the disclosure statement and confirmed the plan Dkt. 595. The plan became effective on September 22, 2023, and the effective-date notice set deadlines for filing certain claims and requests for payment Dkt. 621.
The Oaktree term loan is the only funded debt the filings identify
The first-day declaration describes the debtors' primary long-term debt as approximately $41,875,000 of principal, plus interest, fees and other costs, owed to Oaktree under a Credit Agreement and Guaranty dated June 19, 2020 Dkt. 18 · p. 10. That agreement allowed Athenex to borrow up to $225 million in five tranches at a fixed 11.0% rate, maturing June 19, 2026. Athenex drew $100 million before June 30, 2020, using part of it to repay its credit agreement with Perceptive. It drew two more $25 million tranches before December 31, 2020. The last $75 million depended on approval of Oral Paclitaxel in metastatic breast cancer. It became unavailable when the company stopped pursuing U.S. approval Dkt. 501 · p. 31. Prepayments made under several amendments reduced principal to $41.875 million by the petition date Dkt. 18 · p. 11.
Athenex was the borrower, Oaktree Fund Administration, LLC was administrative agent, and certain debtor subsidiaries guaranteed the loan. The loan was secured by pledges of the equity of all debtor subsidiaries and certain non-debtor subsidiaries. It was also secured by a security interest in substantially all of the debtor obligors' tangible and intangible assets. Oaktree received warrants for up to 908,393 shares of Athenex common stock Dkt. 501. The final cash collateral order recorded the debt as not less than $41.875 million of principal plus accrued interest, fees and other obligations Dkt. 275 · p. 5. Separately, the debtors estimated about $30 million of trade payables at the petition date Dkt. 501 · p. 31. The post-confirmation reports list $45,394,000 of secured claims allowed and paid in full, against $41.875 million of loan principal at the petition date Dkt. 1168.
The case ran on consensual cash collateral, with no DIP loan
The debtors funded the case with the Oaktree lenders' cash collateral, not a DIP loan. The court authorized its use on an interim basis on May 16, 2023 Dkt. 60 and on a final, consensual basis on June 15, 2023. The final order allowed cash use only under an approved budget and gave the prepetition term loan parties adequate protection against any diminution in value. It also tied the case to sale milestones: sale approval orders within 45 days of the petition date and, if applicable, closing within 50 days Dkt. 275.
Sources
- Dkt. 1Chapter 11 Voluntary Petition Non-Individual Fee Amount $1738 Filed by Athenex, Inc.. (Attachments: # 1 Creditor Matrix) (Warner, Michael) (Entered: 05/14/2023)Filed May 14, 2023May 14, 2023
- Dkt. 18First Day DeclarationFiled May 14, 2023May 14, 2023
- Dkt. 60Interim order (I) Authorizing the Debtors to Use Cash Collateral; (II) Granting Adequate Protection to Prepeitition Term Loan Secured Parties; (III) Modifying Automatic Stay; (IV) Scheduling a Final Hearing; and (V) Granting Related Relief Signed on 5/16/2023 (Related document(s):[8] Emergency Motion (with hearing date)) Hearing scheduled for 6/15/2023 at 11:00 AM by telephone and video conference. (VrianaPortillo)Filed May 16, 2023May 16, 2023
- Dkt. 275Final Order (I) Authorizing the Debtors to Use Cash Collateral; (II) Granting Adequate Protection to Prepetition Term Loan Secured Parties; (III) Modifying Automatic Stay; and (IV) Granting Related Relief (Related Doc # [8]) Signed on 6/15/2023. (ElizabethMiller)Cited at p. 5 · Filed Jun 15, 2023Jun 15, 2023
- Dkt. 468Disclosure Statement, Chapter 11 Plan of Reorganization Filed by Athenex, Inc.. (Litvak, Maxim)Filed Jul 26, 2023Jul 26, 2023
- Dkt. 501[Solicitation Version] Disclosure Statement, Chapter 11 Plan of Reorganization Filed by Athenex, Inc.. (Litvak, Maxim) (Entered: 08/01/2023)Cited at p. 31 · Filed Aug 1, 2023Aug 1, 2023
- Dkt. 573Amended Notice of Filing Plan Supplement for the Combined Disclosure Statement and Plan of Liquidation of Athenex, Inc. and its Affiliated Debtors Under Chapter 11 of the Bankruptcy Code. (Related document(s):[468] Disclosure Statement, Chapter 11 Plan, [534] Generic Order, [561] Notice) Filed by Athenex, Inc. (Litvak, Maxim)Filed Sep 5, 2023Sep 5, 2023
- Dkt. 595Order Granting Final Approval of Disclosure Statement and Confirming Plan of Liquidation of Athenex, INC. and its Affiliated Debtors Under Chapter 11 of the Bankruptcy Code Signed on 9/12/2023 (Related document(s):[498] Order Approving Disclosure Statement, [501] Disclosure Statement, Chapter 11 Plan) (VrianaPortillo)Filed Sep 12, 2023Sep 12, 2023
- Dkt. 621Notice of (I) Confirmation and Occurrence of Effective Date of Debtors' Plan of Liquidation and (II) Deadlines for Filing Certain Claims and Requests for Payment. (Related document(s):595 Generic Order) Filed by Athenex, Inc. (Litvak, Maxim)Filed Sep 22, 2023Sep 22, 2023
- Dkt. 1143Liquidating Trustee Settlement and Asset AssignmentFiled Mar 11, 2026Mar 11, 2026
- Dkt. 1144Withdrawal of Claim 10039Filed Mar 13, 2026Mar 13, 2026
- Dkt. 1147Order Extending Claims Objection DeadlineFiled Mar 16, 2026Mar 16, 2026
- Dkt. 1151Post-Confirmation Report (Q1 2026)Filed Apr 21, 2026Apr 21, 2026
- Dkt. 1152Notice of Forfeited DistributionsFiled May 6, 2026May 6, 2026
- Dkt. 1155Objection to Duplicate Claim 10325Filed Jun 25, 2026Jun 25, 2026
- Dkt. 1156Declaration Supporting Objection to Lau ClaimFiled Jun 25, 2026Jun 25, 2026
- Dkt. 1160Post-Confirmation ReportFiled Jul 17, 2026Jul 17, 2026
- Dkt. 1161Claims Objection ExtensionFiled Jul 17, 2026Jul 17, 2026
- Dkt. 1165Lau Claim Objection SustainedFiled Aug 12, 2026Aug 12, 2026
- Dkt. 1168Quarterly Post-Confirmation ReportFiled Oct 22, 2026Oct 22, 2026
- Dkt. 1174Claims Deadline SupplementFiled Nov 4, 2026Nov 4, 2026
- Dkt. 1176Claims Objection Deadline ExtendedFiled Nov 16, 2026Nov 16, 2026